Loading...

Thompson, Leslie M

TitleProfessor
InstitutionUniversity of California, Irvine
DepartmentPsychiatry & Human Behavior
Address1001 Health Sciences Road
CA 92697-3950
Phone(949) 824-6756, 1910
vCardDownload vCard
    Other Positions
    TitleProfessor


    Collapse Research 
    Collapse Research Activities and Funding
    From Structure to Therapy: The TRiC Chaperonin Network in Huntington's Disease
    NIH/NINDS P01NS092525Apr 1, 2016 - Mar 31, 2021
    Role: Principal Investigator
    Neuroregulatory Mechanisms of PIAS1 and Implications for Huntington's Disease
    NIH/NINDS R01NS090390Jul 15, 2015 - Jun 30, 2019
    Role: Principal Investigator
    Genome editing in HD iPS cells to reduce mutant and total Huntington expression
    NIH/NINDS R21NS090395Jul 15, 2015 - Jun 30, 2017
    Role: Principal Investigator
    Epigenetic pathology and therapy in Huntington's disease
    NIH/NINDS R01NS089076Apr 1, 2015 - Mar 31, 2020
    Role: Co-Principal Investigator
    Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells
    NIH/NINDS U54NS091046Sep 30, 2014 - Jun 30, 2020
    Role: Principal Investigator
    Neuroregulatory Mechanisms of PIAS1 and Implications for Huntington's Disease
    NIH/NINDS R56NS090390Sep 30, 2014 - Aug 31, 2015
    Role: Principal Investigator
    In vivo longitudinal assessment of methylene blue for Huntington's disease
    NIH/NINDS R03NS081260Jan 1, 2014 - Aug 31, 2016
    Role: Principal Investigator
    Training Program in Stem Cell Translational Medicine for Neurological Disorders
    NIH/NINDS T32NS082174Jul 1, 2013 - Jun 30, 2023
    Role: Principal Investigator
    CAG Triplet Repeat Disorders
    NIH/NINDS R13NS083250Apr 1, 2013 - Mar 31, 2014
    Role: Principal Investigator
    The HD iPSC Consortium: Repeat Length Dependent Phenotypes for Assay Development
    NIH/NINDS U24NS078370Jul 1, 2012 - Jun 30, 2014
    Role: Principal Investigator
    The Histone Demethylase SMCX/JARED1C as a Therapeutic Target for Huntington's Dis
    NIH/NINDS R21NS072793Apr 1, 2011 - Mar 31, 2013
    Role: Principal Investigator
    The Huntington's Disease iPS Consortium
    NIH/NINDS RC2NS069422Sep 30, 2009 - Aug 31, 2012
    Role: Co-Principal Investigator
    Pathogenic Impact of SUMO modification in Huntington's disease
    NIH/NINDS R01NS052789Jun 1, 2006 - May 31, 2012
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Ochaba J, Morozko EL, O'Rourke JG, Thompson L. Fractionation for Resolution of Soluble and Insoluble Huntingtin Species. J Vis Exp. 2018 Feb 27; (132). PMID: 29553509.
      View in: PubMed
    2. Geater C, Hernandez S, Thompson L, Mattis VB. Cellular Models: HD Patient-Derived Pluripotent Stem Cells. Methods Mol Biol. 2018; 1780:41-73. PMID: 29856014.
      View in: PubMed
    3. Reidling JC, Relaño-Ginés A, Holley SM, Ochaba J, Moore C, Fury B, Lau A, Tran AH, Yeung S, Salamati D, Zhu C, Hatami A, Cepeda C, Barry JA, Kamdjou T, King A, Coleal-Bergum D, Franich NR, LaFerla FM, Steffan JS, Blurton-Jones M, Meshul CK, Bauer G, Levine MS, Chesselet MF, Thompson L. Human Neural Stem Cell Transplantation Rescues Functional Deficits in R6/2 and Q140 Huntington's Disease Mice. Stem Cell Reports. 2018 Jan 09; 10(1):58-72. PMID: 29233555.
      View in: PubMed
    4. Lim RG, Quan C, Reyes-Ortiz AM, Lutz SE, Kedaigle AJ, Gipson TA, Wu J, Vatine GD, Stocksdale J, Casale MS, Svendsen CN, Fraenkel E, Housman DE, Agalliu D, Thompson L. Huntington's Disease iPSC-Derived Brain Microvascular Endothelial Cells Reveal WNT-Mediated Angiogenic and Blood-Brain Barrier Deficits. Cell Rep. 2017 05 16; 19(7):1365-1377. PMID: 28514657.
      View in: PubMed
    5. Ochaba J, Monteys AM, O'Rourke JG, Reidling JC, Steffan JS, Davidson BL, Thompson L. PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In Vivo. Neuron. 2016 05 04; 90(3):507-20. PMID: 27146268; PMCID: PMC4942306 [Available on 05/04/17].
    6. Lee JH, Tecedor L, Chen YH, Monteys AM, Sowada MJ, Thompson L, Davidson BL. Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes. Neuron. 2015 Jan 21; 85(2):303-15. PMID: 25556834.
      View in: PubMed
    7. Liu KY, Shyu YC, Barbaro BA, Lin YT, Chern Y, Thompson L, James Shen CK, Marsh JL. Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease. Hum Mol Genet. 2015 Mar 15; 24(6):1602-16. PMID: 25398943; PMCID: PMC4381756.
    8. Ochaba J, Lukacsovich T, Csikos G, Zheng S, Margulis J, Salazar L, Mao K, Lau AL, Yeung SY, Humbert S, Saudou F, Klionsky DJ, Finkbeiner S, Zeitlin SO, Marsh JL, Housman DE, Thompson L, Steffan JS. Potential function for the Huntingtin protein as a scaffold for selective autophagy. Proc Natl Acad Sci U S A. 2014 Nov 25; 111(47):16889-94. PMID: 25385587; PMCID: PMC4250109.
    9. Salazar L, Kashiwada T, Krejci P, Meyer AN, Casale M, Hallowell M, Wilcox WR, Donoghue DJ, Thompson L. Fibroblast growth factor receptor 3 interacts with and activates TGFß-activated kinase 1 tyrosine phosphorylation and NF?B signaling in multiple myeloma and bladder cancer. PLoS One. 2014; 9(1):e86470. PMID: 24466111; PMCID: PMC3900522.
    10. Vashishtha M, Ng CW, Yildirim F, Gipson TA, Kratter IH, Bodai L, Song W, Lau A, Labadorf A, Vogel-Ciernia A, Troncosco J, Ross CA, Bates GP, Krainc D, Sadri-Vakili G, Finkbeiner S, Marsh JL, Housman DE, Fraenkel E, Thompson L. Targeting H3K4 trimethylation in Huntington disease. Proc Natl Acad Sci U S A. 2013 Aug 06; 110(32):E3027-36. PMID: 23872847; PMCID: PMC3740882.
    11. O'Rourke JG, Gareau JR, Ochaba J, Song W, Raskó T, Reverter D, Lee J, Monteys AM, Pallos J, Mee L, Vashishtha M, Apostol BL, Nicholson TP, Illes K, Zhu YZ, Dasso M, Bates GP, Difiglia M, Davidson B, Wanker EE, Marsh JL, Lima CD, Steffan JS, Thompson L. SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation. Cell Rep. 2013 Jul 25; 4(2):362-75. PMID: 23871671.
      View in: PubMed
    12. Sontag EM, Joachimiak LA, Tan Z, Tomlinson A, Housman DE, Glabe CG, Potkin SG, Frydman J, Thompson L. Exogenous delivery of chaperonin subunit fragment ApiCCT1 modulates mutant Huntingtin cellular phenotypes. Proc Natl Acad Sci U S A. 2013 Feb 19; 110(8):3077-82. PMID: 23365139; PMCID: PMC3581981.
    13. Sontag EM, Lotz GP, Agrawal N, Tran A, Aron R, Yang G, Necula M, Lau A, Finkbeiner S, Glabe C, Marsh JL, Muchowski PJ, Thompson L. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models. J Neurosci. 2012 Aug 08; 32(32):11109-19. PMID: 22875942; PMCID: PMC3546821.
    14. Sontag EM, Lotz GP, Yang G, Sontag CJ, Cummings BJ, Glabe CG, Muchowski PJ, Thompson L. Detection of Mutant Huntingtin Aggregation Conformers and Modulation of SDS-Soluble Fibrillar Oligomers by Small Molecules. J Huntingtons Dis. 2012; 1(1):119-32. PMID: 24086178; PMCID: PMC3786168.
    15. Strong MK, Southwell AL, Yonan JM, Hayden MR, Macgregor GR, Thompson L, Steward O. Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background. J Huntingtons Dis. 2012; 1(2):221-41. PMID: 23833693; PMCID: PMC3702054.
    16. Bodai L, Pallos J, Thompson L, Marsh JL. Pcaf modulates polyglutamine pathology in a Drosophila model of Huntington's disease. Neurodegener Dis. 2012; 9(2):104-6. PMID: 21912091; PMCID: PMC3304510.
    17. Sleiman SF, Langley BC, Basso M, Berlin J, Xia L, Payappilly JB, Kharel MK, Guo H, Marsh JL, Thompson L, Mahishi L, Ahuja P, MacLellan WR, Geschwind DH, Coppola G, Rohr J, Ratan RR. Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. J Neurosci. 2011 May 04; 31(18):6858-70. PMID: 21543616; PMCID: PMC3717375.
    18. Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, Finkbeiner S, Steffan JS, Thompson L, Wetzel R, Yang XW. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron. 2009 Dec 24; 64(6):828-40. PMID: 20064390; PMCID: PMC2807408.
    19. Thompson L, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnan A, Martinez-Vincente M, Arrasate M, O'Rourke JG, Khashwji H, Lukacsovich T, Zhu YZ, Lau AL, Massey A, Hayden MR, Zeitlin SO, Finkbeiner S, Green KN, LaFerla FM, Bates G, Huang L, Patterson PH, Lo DC, Cuervo AM, Marsh JL, Steffan JS. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol. 2009 Dec 28; 187(7):1083-99. PMID: 20026656; PMCID: PMC2806289.
    20. Aiken CT, Steffan JS, Guerrero CM, Khashwji H, Lukacsovich T, Simmons D, Purcell JM, Menhaji K, Zhu YZ, Green K, Laferla F, Huang L, Thompson L, Marsh JL. Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J Biol Chem. 2009 Oct 23; 284(43):29427-36. PMID: 19710014; PMCID: PMC2785575.
    21. Salazar L, Kashiwada T, Krejci P, Muchowski P, Donoghue D, Wilcox WR, Thompson L. A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells. Hum Mol Genet. 2009 Jun 01; 18(11):1951-61. PMID: 19286672; PMCID: PMC2902846.
    22. Krejci P, Salazar L, Kashiwada TA, Chlebova K, Salasova A, Thompson L, Bryja V, Kozubik A, Wilcox WR. Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage. PLoS One. 2008; 3(12):e3961. PMID: 19088846; PMCID: PMC2597732.
    23. Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson L, LaFerla FM. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci. 2008 Nov 05; 28(45):11500-10. PMID: 18987186; PMCID: PMC2617713.
    24. Marsh JL, Lukacsovich T, Thompson L. Animal models of polyglutamine diseases and therapeutic approaches. J Biol Chem. 2009 Mar 20; 284(12):7431-5. PMID: 18957429; PMCID: PMC2658038.
    25. Krejci P, Prochazkova J, Bryja V, Jelinkova P, Pejchalova K, Kozubik A, Thompson L, Wilcox WR. Fibroblast growth factor inhibits interferon gamma-STAT1 and interleukin 6-STAT3 signaling in chondrocytes. Cell Signal. 2009 Jan; 21(1):151-60. PMID: 18950705; PMCID: PMC2655766.
    26. Pallos J, Bodai L, Lukacsovich T, Purcell JM, Steffan JS, Thompson L, Marsh JL. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet. 2008 Dec 01; 17(23):3767-75. PMID: 18762557; PMCID: PMC2581431.
    27. Conforti P, Ramos C, Apostol BL, Simmons DA, Nguyen HP, Riess O, Thompson L, Zuccato C, Cattaneo E. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347. Mol Cell Neurosci. 2008 Sep; 39(1):1-7. PMID: 18571429.
      View in: PubMed
    28. Apostol BL, Simmons DA, Zuccato C, Illes K, Pallos J, Casale M, Conforti P, Ramos C, Roarke M, Kathuria S, Cattaneo E, Marsh JL, Thompson L. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol Cell Neurosci. 2008 Sep; 39(1):8-20. PMID: 18602275.
      View in: PubMed
    29. Thompson L. Neurodegeneration: a question of balance. Nature. 2008 Apr 10; 452(7188):707-8. PMID: 18401401.
      View in: PubMed
    30. Krejci P, Salazar L, Goodridge HS, Kashiwada TA, Schibler MJ, Jelinkova P, Thompson L, Wilcox WR. STAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytes. J Cell Sci. 2008 Feb 01; 121(Pt 3):272-81. PMID: 18198189.
      View in: PubMed
    31. McLin JP, Thompson L, Lusis AJ, Davis RC, Steward O. Genes on distal chromosome 18 determine vulnerability to excitotoxic neurodegeneration following status epilepticus, but not striatal neurodegeneration induced by quinolinic acid. Neurobiol Dis. 2008 Mar; 29(3):391-9. PMID: 17996456.
      View in: PubMed
    32. Krejci P, Masri B, Salazar L, Farrington-Rock C, Prats H, Thompson L, Wilcox WR. Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins. J Biol Chem. 2007 Feb 02; 282(5):2929-36. PMID: 17145761.
      View in: PubMed
    33. McLin JP, Thompson L, Steward O. Differential susceptibility to striatal neurodegeneration induced by quinolinic acid and kainate in inbred, outbred and hybrid mouse strains. Eur J Neurosci. 2006 Dec; 24(11):3134-40. PMID: 17156374.
      View in: PubMed
    34. Rockabrand E, Slepko N, Pantalone A, Nukala VN, Kazantsev A, Marsh JL, Sullivan PG, Steffan JS, Sensi SL, Thompson L. The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet. 2007 Jan 01; 16(1):61-77. PMID: 17135277.
      View in: PubMed
    35. Ross CA, Thompson L. Transcription meets metabolism in neurodegeneration. Nat Med. 2006 Nov; 12(11):1239-41. PMID: 17088887.
      View in: PubMed
    36. Marsh JL, Thompson L. Drosophila in the study of neurodegenerative disease. Neuron. 2006 Oct 05; 52(1):169-78. PMID: 17015234.
      View in: PubMed
    37. Slepko N, Bhattacharyya AM, Jackson GR, Steffan JS, Marsh JL, Thompson L, Wetzel R. Normal-repeat-length polyglutamine peptides accelerate aggregation nucleation and cytotoxicity of expanded polyglutamine proteins. Proc Natl Acad Sci U S A. 2006 Sep 26; 103(39):14367-72. PMID: 16980414; PMCID: PMC1599969.
    38. Desai UA, Pallos J, Ma AA, Stockwell BR, Thompson L, Marsh JL, Diamond MI. Biologically active molecules that reduce polyglutamine aggregation and toxicity. Hum Mol Genet. 2006 Jul 01; 15(13):2114-24. PMID: 16720620.
      View in: PubMed
    39. Apostol BL, Illes K, Pallos J, Bodai L, Wu J, Strand A, Schweitzer ES, Olson JM, Kazantsev A, Marsh JL, Thompson L. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum Mol Genet. 2006 Jan 15; 15(2):273-85. PMID: 16330479.
      View in: PubMed
    40. Nowroozi N, Raffioni S, Wang T, Apostol BL, Bradshaw RA, Thompson L. Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells. Hum Mol Genet. 2005 Jun 01; 14(11):1529-38. PMID: 15843401.
      View in: PubMed
    41. Agrawal N, Pallos J, Slepko N, Apostol BL, Bodai L, Chang LW, Chiang AS, Thompson L, Marsh JL. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc Natl Acad Sci U S A. 2005 Mar 08; 102(10):3777-81. PMID: 15716359; PMCID: PMC553288.
    42. Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M, Washington SL, Maxwell MM, Marsh JL, Thompson L, Wanker EE, Young AB, Housman DE, Bates GP, Sherman MY, Kazantsev AG. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A. 2005 Jan 18; 102(3):892-7. PMID: 15642944; PMCID: PMC545525.
    43. Marsh JL, Thompson L. Can flies help humans treat neurodegenerative diseases? Bioessays. 2004 May; 26(5):485-96. PMID: 15112229.
      View in: PubMed
    44. Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, Slepko N, Illes K, Lukacsovich T, Zhu YZ, Cattaneo E, Pandolfi PP, Thompson L, Marsh JL. SUMO modification of Huntingtin and Huntington's disease pathology. Science. 2004 Apr 02; 304(5667):100-4. PMID: 15064418.
      View in: PubMed
    45. Pollitt SK, Pallos J, Shao J, Desai UA, Ma AA, Thompson L, Marsh JL, Diamond MI. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron. 2003 Nov 13; 40(4):685-94. PMID: 14622574.
      View in: PubMed
    46. Qin ZH, Wang Y, Kegel KB, Kazantsev A, Apostol BL, Thompson L, Yoder J, Aronin N, DiFiglia M. Autophagy regulates the processing of amino terminal huntingtin fragments. Hum Mol Genet. 2003 Dec 15; 12(24):3231-44. PMID: 14570716.
      View in: PubMed
    47. Thompson L. An expanded role for wild-type huntingtin in neuronal transcription. Nat Genet. 2003 Sep; 35(1):13-4. PMID: 12947403.
      View in: PubMed
    48. Thompson L, Marsh JL. Invertebrate models of neurologic disease: insights into pathogenesis and therapy. Curr Neurol Neurosci Rep. 2003 Sep; 3(5):442-8. PMID: 12914688.
      View in: PubMed
    49. Marsh JL, Pallos J, Thompson L. Fly models of Huntington's disease. Hum Mol Genet. 2003 Oct 15; 12 Spec No 2:R187-93. PMID: 12925571.
      View in: PubMed
    50. Apostol BL, Kazantsev A, Raffioni S, Illes K, Pallos J, Bodai L, Slepko N, Bear JE, Gertler FB, Hersch S, Housman DE, Marsh JL, Thompson L. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci U S A. 2003 May 13; 100(10):5950-5. PMID: 12730384; PMCID: PMC156307.
    51. Steffan JS, Thompson L. Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases. Expert Opin Ther Targets. 2003 Apr; 7(2):201-13. PMID: 12667098.
      View in: PubMed